Mylan Launches US Advair Rival, Wixela Inhub, At A 70% Discount
Mylan has launched its Wixela Inhub rival to GSK’s Advair Diskus at a 70% discount to the brand price.
You may also be interested in...
Hikma has provided a trading update that sheds fresh light on plans for its delayed Advair generic, as well as revealing some new launches.
Hikma has received another setback on its US application for a generic version of Advair following a minor complete response letter from the FDA. The resulting delay will push back the expected final response date from the agency closer to that expected by rival Cipla, which filed an ANDA earlier this year.
Lannett has partnered with China’s Respirent for a generic version of GlaxoSmithKline’s Flovent Diskus. At the same time, the US company has extended its exclusive US distribution rights for Respirent’s Advair Diskus rival from 10 years to 12 years, as Lannett remains on track to file its ANDA this calendar year.